guest ::
| Home > Publications Database > Autophagy activation ameliorates cognitive deficits and alpha-synuclein pathology in an adeno-associated viral vector mediated rat model of Lewy body disorders. > print |
| Home > Publications Database > Autophagy activation ameliorates cognitive deficits and alpha-synuclein pathology in an adeno-associated viral vector mediated rat model of Lewy body disorders. > print |
| 001 | 281436 | ||
| 005 | 20260105130637.0 | ||
| 024 | 7 | _ | |a 10.1016/j.pbb.2025.174096 |2 doi |
| 024 | 7 | _ | |a pmid:40939811 |2 pmid |
| 024 | 7 | _ | |a 0091-3057 |2 ISSN |
| 024 | 7 | _ | |a 1873-5177 |2 ISSN |
| 024 | 7 | _ | |a altmetric:181541009 |2 altmetric |
| 037 | _ | _ | |a DZNE-2025-01121 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 540 |
| 100 | 1 | _ | |a Cinar, Elif |b 0 |
| 245 | _ | _ | |a Autophagy activation ameliorates cognitive deficits and alpha-synuclein pathology in an adeno-associated viral vector mediated rat model of Lewy body disorders. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2025 |b Elsevier Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1762876849_13692 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Lewy body disorders (LBD), including Parkinson's disease (PD), Parkinson's disease with dementia (PDD), and dementia with Lewy bodies (DLB), are characterized by the aggregation of alpha-synuclein (a-syn). Despite shared pathological features, these disorders have distinct clinical characteristics, in terms of both motor and cognitive symptoms. We created a unique rat model of dual-site injection of adeno-associated viral vectors carrying human a-syn (AAV5-h-a-syn) simultaneously and bilaterally into the substantia nigra and dentate gyrus, to recapitulate both nigrostriatal and hippocampal-based a-syn pathology associated with PDD and DLB. Inspired by the distinct pathological features of the model, namely the CA2-dominated accumulation of phosphorylated a-syn, in the current study we aimed to evaluate comparatively the consequences of autophagic induction on a-syn pathology in these targeted areas. This was achieved by the chronic administration of rapamycin, for 8 weeks starting 10 weeks post-AAV injections. Behavioral assessments were conducted by evaluation of locomotor activity, anxiety-related behavior, object and spatial learning and memory. Histopathological examinations involved in-depth analysis of a-syn pathology, neuronal and synaptic integrity and autophagic markers. Results demonstrated that rapamycin significantly ameliorated cognitive deficits and reduced phosphorylated a-syn accumulation, significantly in CA2 throughout all its sublayers and partially in CA3 sublayers. Despite no alteration in NeuN and TH levels, synaptophysin expressions were decreased in both the hippocampus and striatum in a-syn overexpressing animals, which were partially restored by rapamycin treatment. Intriguingly, autophagic activation, as indicated by the increased expression of beclin-1, LC3-I/II, p62, and Atg proteins, was predominantly observed in the hippocampus but not in the striatum, suggesting region-specific differential response to autophagic induction in terms of a-syn pathology. This dual-site injection model provides a valuable tool for studying a-syn-related dementia and evaluating potential restorative therapies. Our findings underscore the importance of autophagy-targeting early interventions to alleviate cognitive deficits by reducing hippocampal a-syn burden in LBD. |
| 536 | _ | _ | |a 352 - Disease Mechanisms (POF4-352) |0 G:(DE-HGF)POF4-352 |c POF4-352 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Alpha-synucleinopathies |2 Other |
| 650 | _ | 7 | |a CA2 |2 Other |
| 650 | _ | 7 | |a Dementia |2 Other |
| 650 | _ | 7 | |a Hippocampus |2 Other |
| 650 | _ | 7 | |a Parkinson's disease |2 Other |
| 650 | _ | 7 | |a Rapamycin |2 Other |
| 650 | _ | 7 | |a Stratum pyramidale |2 Other |
| 650 | _ | 7 | |a Synaptic integrity |2 Other |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a alpha-Synuclein: metabolism |2 MeSH |
| 650 | _ | 2 | |a alpha-Synuclein: genetics |2 MeSH |
| 650 | _ | 2 | |a Autophagy: drug effects |2 MeSH |
| 650 | _ | 2 | |a Autophagy: physiology |2 MeSH |
| 650 | _ | 2 | |a Rats |2 MeSH |
| 650 | _ | 2 | |a Dependovirus: genetics |2 MeSH |
| 650 | _ | 2 | |a Lewy Body Disease: pathology |2 MeSH |
| 650 | _ | 2 | |a Lewy Body Disease: metabolism |2 MeSH |
| 650 | _ | 2 | |a Lewy Body Disease: psychology |2 MeSH |
| 650 | _ | 2 | |a Lewy Body Disease: therapy |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Disease Models, Animal |2 MeSH |
| 650 | _ | 2 | |a Genetic Vectors |2 MeSH |
| 650 | _ | 2 | |a Cognitive Dysfunction: therapy |2 MeSH |
| 650 | _ | 2 | |a Sirolimus: pharmacology |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Rats, Sprague-Dawley |2 MeSH |
| 700 | 1 | _ | |a Yalcin-Cakmakli, Gül |b 1 |
| 700 | 1 | _ | |a Akyel, Hilal |b 2 |
| 700 | 1 | _ | |a Ulusoy, Ayse |0 P:(DE-2719)2772760 |b 3 |u dzne |
| 700 | 1 | _ | |a Tel, Banu Cahide |b 4 |
| 700 | 1 | _ | |a Elibol, Bülent |b 5 |
| 773 | _ | _ | |a 10.1016/j.pbb.2025.174096 |g Vol. 257, p. 174096 - |0 PERI:(DE-600)2008734-2 |p 174096 |t Pharmacology, biochemistry and behavior |v 257 |y 2025 |x 0091-3057 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/281436/files/DZNE-2025-01121%20SUP.zip |
| 856 | 4 | _ | |u https://pub.dzne.de/record/281436/files/DZNE-2025-01121_Restricted.pdf |
| 856 | 4 | _ | |u https://pub.dzne.de/record/281436/files/DZNE-2025-01121_Restricted.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |p VDB |o oai:pub.dzne.de:281436 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 3 |6 P:(DE-2719)2772760 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-352 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Mechanisms |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-13 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-13 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-13 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b PHARMACOL BIOCHEM BE : 2022 |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-13 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-13 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2024-12-13 |
| 920 | 1 | _ | |0 I:(DE-2719)1013044 |k AG Ulusoy |l Parkinson's and Spatial Omics |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1013044 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|